Epithelial-mesenchymal transition and drug resistance in breast cancer (Review)

International Journal of Oncology

Volumn 47, Issue 3, 2015, Pages 840-848

  Huang, Jing ^a   Li, Hongzhong ^a   Ren, Guosheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Cancer stem cells; Drug resistance; Epithelial mesenchymal transition; MicroRNA

Indexed keywords

CYTOKINE; MICRORNA; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR GENE; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; SIGNAL TRANSDUCTION;

EID: 84938099381     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3084     Document Type: Review

References (108)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Hernandez-Aya LF and Gonzalez-Angulo AM: Adjuvant systemic therapies in breast cancer. Surg Clin North Am 93: 473-491, 2013.
3. Collignon J, Rorive A, Martin M, Andre C, Maweja S, Lifrange E, Coucke P and Jerusalem G: Systemic chemotherapy and breast cancer. Rev Med Liege 66: 372-378, 2011 (In French).
4. Saeki T, Tsuruo T, Sato W and Nishikawsa K: Drug resistance in chemotherapy for breast cancer. Cancer Chemother Pharmacol 56 (Suppl 1): 84-89, 2005.
5. Coley HM: Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 34: 378-390, 2008.
6. Roxanis I: Occurrence and significance of epithelial-mesenchymal transition in breast cancer. J Clin Pathol 66: 517-521, 2013.
7. Wang Y and Zhou BP : Epithelial-mesenchymal transition - a hallmark of breast cancer metastasis. Cancer Hallm 1: 38-49, 2013.
8. Dave B, Mittal V, Tan NM and Chang JC: Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res 14: 202, 2012.
9. Mallini P, Lennard T, Kirby J and Meeson A: Epithelial-tomesenchymal transition: What is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev 40: 341-348, 2014.
10. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234, 2006.
11. G onzalez-Angulo AM, Morales-Vasquez F and Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22, 2007.
12. Dean M: ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 14: 3-9, 2009.
13. Shah PD and Dickler MN: Endocrine therapy for advanced breast cancer. Clin Adv Hematol Oncol 12: 214-223, 2014.
14. Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A and Perrone F; NCI-Naple Breast Cancer Group: Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 12: 721-747, 2005.
15. Al Saleh S, Sharaf LH and Luqmani YA: Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). Int J Oncol 38: 1197-1217, 2011.
16. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et al; Breast Cancer International Research Group: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365: 1273-1283, 2011.
17. Martin-Castillo B, Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Moreno JM, Corominas-Faja B, Urruticoechea A, Martín ?G, López-Bonet E and Menendez JA: Basal/HER2 breast carcinomas: Integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle 12: 225-245, 2013.
18. G ajria D and Chandarlapaty S: HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 11: 263-275, 2011.
19. Foroni C, Broggini M, Generali D and Damia G: Epithelialmesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact. Cancer Treat Rev 38: 689-697, 2012.
20. Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142, 2006.
21. Voulgari A and Pintzas A: Epithelial-mesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796: 75-90, 2009.
22. B ezdenezhnykh N, Semesiuk N, Lykhova O, Zhylchuk V and Kudryavets Y: Impact of stromal cell components of tumor microenvironment on epithelial-mesenchymal transition in breast cancer cells. Exp Oncol 36: 72-78, 2014.
23. Bonde AK, Tischler V, Kumar S, Soltermann A and Schwendener RA: Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer 12: 35, 2012.
24. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL and Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348, 2005.
25. Yang J and Weinberg RA: Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell 14: 818-829, 2008.
26. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelialmesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
27. Vega S, Morales AV, Ocaña OH, Valdés F, Fabregat I and Nieto MA: Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 18: 1131-1143, 2004.
28. Kajita M, McClinic KN and Wade PA: Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol Cell Biol 24: 7559-7566, 2004.
29. Chen WJ, Wang H, Tang Y, Liu CL, Li HL and Li WT: Multidrug resistance in breast cancer cells during epithelial-mesenchymal transition is modulated by breast cancer resistant protein. Chin J Cancer 29: 151-157, 2010.
30. Li W, Liu C, Tang Y, Li H, Zhou F and Lv S: Overexpression of Snail accelerates adriamycin induction of multidrug resistance in breast cancer cells. Asian Pac J Cancer Prev 12: 2575-2580, 2011.
31. Prasad CP, Rath G, Mathur S, Bhatnagar D, Parshad R and Ralhan R: Expression analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma of breast. BMC Cancer 9: 325, 2009.
32. Iseri OD, Kars MD, Arpaci F, Atalay C, Pak I and Gunduz U: Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed Pharmacother 65: 40-45, 2011.
33. Luqmani YA, Al Azmi A, Al Bader M, Abraham G and El Z awahri M: Modification of gene expression induced by siRNA targeting of estrogen receptor alpha in MCF7 human breast cancer cells. Int J Oncol 34: 231-242, 2009.
34. Andreeva OE, Shcherbakov AM, Shatskaia VA and Krasilńikov MA: The role of transcription factor Snail1 in the regulation of hormonal sensitivity of in vitro cultured breast cancer cells. Vopr Onkol 58: 71-76, 2012 (In Russian).
35. Dhasarathy A, Kajita M and Wade PA: The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha. Mol Endocrinol 21: 2907-2918, 2007.
36. Ye Y, Xiao Y, Wang W, Yearsley K, Gao JX and Barsky SH: ERalpha suppresses slug expression directly by transcriptional repression. Biochem J 416: 179-187, 2008.
37. Cheng GZ , Chan J, Wang Q, Zhang W, Sun CD and Wang LH: Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 67: 1979-1987, 2007.
38. Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F, Chen Z Q, Liu XP and Xu ZD: Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 15: 2657-2665, 2009.
39. Saxena M, Stephens MA, Pathak H and Rangarajan A: Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis 2: e179, 2011.
40. Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT, De K and Sun LZ: Doxorubicin in combination with a small TGFbeta inhibitor: A potential novel therapy for metastatic breast cancer in mouse models. PLoS One 5: e10365, 2010.
41. Hirohashi S and Kanai Y: Cell adhesion system and human cancer morphogenesis. Cancer Sci 94: 575-581, 2003.
42. López-Díaz FJ, Gascard P, Balakrishnan SK, Zhao J, Del Rincon SV, Spruck C, Tlsty TD and Emerson BM: Coordinate transcriptional and translational repression of p53 by TGF-β1 impairs the stress response. Mol Cell 50: 552-564, 2013.
43. Shi XP, Miao S, Wu Y, Zhang W, Zhang XF, Ma HZ, Xin HL, Feng J, Wen AD and Li Y: Resveratrol sensitizes tamoxifen in antiestrogen-resistant breast cancer cells with epithelial-mesenchymal transition features. Int J Mol Sci 14: 15655-15668, 2013.
44. Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, Pandiella A and Arteaga CL: Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol 28: 5605-5620, 2008.
45. Walsh LA and Damjanovski S: IGF-1 increases invasive potential of MCF-7 breast cancer cells and induces activation of latent TGF-β1 resulting in epithelial to mesenchymal transition. Cell Commun Signal 9: 10, 2011.
46. Gooch JL, Van Den Berg CL and Yee D: Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapyinduced cell death - proliferative and anti-apoptotic effects. Breast Cancer Res Treat 56: 1-10, 1999.
47. Nahta R, Yuan LX, Zhang B, Kobayashi R and Esteva FJ: Insulinlike growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65: 11118-11128, 2005.
48. G an Y, Wientjes MG and Au JL: Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res 23: 1324-1331, 2006.
49. McLeskey SW, Zhang L, El-Ashry D, Trock BJ, Lopez CA, Kharbanda S, Tobias CA, Lorant LA, Hannum RS, Dickson RB, et al: Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors. Clin Cancer Res 4: 697-711, 1998.
50. Magnani L, Stoeck A, Zhang X, Lánczky A, Mirabella AC, Wang TL, Gyorffy B and Lupien M: Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc Natl Acad Sci USA 110: E1490-E1499, 2013.
51. Z hang CC, Yan Z, Zong Q, Fang DD, Painter C, Zhang Q, Chen E, Lira ME, John-Baptiste A and Christensen JG: Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models. Stem Cells Transl Med 2: 233-242, 2013.
52. P andya K, Meeke K, Clementz AG, Rogowski A, Roberts J, Miele L, Albain KS and Osipo C: Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB- 2-positive breast tumour recurrence. Br J Cancer 105: 796-806, 2011.
53. O rlowski RZ and Baldwin AS Jr: NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8: 385-389, 2002.
54. Tapia MA, González-Navarrete I, Dalmases A, Bosch M, Rodriguez-Fanjul V, Rolfe M, Ross JS, Mezquita J, Mezquita C, Bachs O, et al: Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. Cell Cycle 6: 2284-2292, 2007.
55. Musgrove EA and Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9: 631-643, 2009.
56. G ee JM, Robertson JF, Ellis IO and Nicholson RI: Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95: 247-254, 2001.
57. B erns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402, 2007.
58. Loh YN, Hedditch EL, Baker LA, Jary E, Ward RL and Ford CE: The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer 13: 174, 2013.
59. Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D and Vadgama JV: Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumabresistant HER2-overexpressing breast cancer cells. Mol Cancer Res 10: 1597-1606, 2012.
60. Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J and Mehta K: Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One 5: e13390, 2010.
61. Liu Y, Du F, Chen W, Yao M, Lv K and Fu P: Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin. Exp Cell Res 319: 3140-3149, 2013.
62. Kim MR, Choi HK, Cho KB, Kim HS and Kang KW: Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells. Cancer Sci 100: 1834-1841, 2009.
63. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC and Knutson KL: AXL induces epithelial-tomesenchymal transition and regulates the function of breast cancer stem cells. Oncogene 33: 1316-1324, 2014.
64. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ and Wicha MS: In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17: 1253-1270, 2003.
65. Donnenberg VS and Donnenberg AD: Multiple drug resistance in cancer revisited: The cancer stem cell hypothesis. J Clin Pharmacol 45: 872-877, 2005.
66. Jordan CT, Guzman ML and Noble M: Cancer stem cells. N Engl J Med 355: 1253-1261, 2006.
67. Kakarala M and Wicha MS: Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 26: 2813-2820, 2008.
68. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S and Puisieux A: Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3: e2888, 2008.
69. Radisky DC and LaBarge MA: Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell 2: 511-512, 2008.
70. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, et al: Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 69: 2887-2895, 2009.
71. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R and Kasimir-Bauer S: Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 11: R46, 2009.
72. Lee JM, Dedhar S, Kalluri R and Thompson EW: The epithelialmesenchymal transition: New insights in signaling, development, and disease. J Cell Biol 172: 973-981, 2006.
73. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB , Evans KW, et al: Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 107: 15449-15454, 2010.
74. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715, 2008.
75. Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H and Pals ST: Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 154: 515-523, 1999.
76. Vesuna F, Lisok A, Kimble B and Raman V: Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia 11: 1318-1328, 2009.
77. Li J and Zhou BP : Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer 11: 49, 2011.
78. Fang X, Cai Y, Liu J, Wang Z, Wu Q, Zhang Z, Yang CJ, Yuan L and Ouyang G: Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal. Oncogene 30: 4707-4720, 2011.
79. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, et al: The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 11: 1487-1495, 2009.
80. Park SM, Gaur AB, Lengyel E and Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22: 894-907, 2008.
81. G uo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, Itzkovitz S, Noske A, Zürrer-Härdi U, Bell G, et al: Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148: 1015-1028, 2012.
82. P ályi-Krekk Z, Barok M, Isola J, Tammi M, Szöllosi J and Nagy P : Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer 43: 2423-2433, 2007.
83. Lesniak D, Sabri S, Xu Y, Graham K, Bhatnagar P, Suresh M and Abdulkarim B: Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer. PLoS One 8: e71987, 2013.
84. O liveras-Ferraros C, Corominas-Faja B, Cufí S, Vazquez-Martin A, Martin-Castillo B, Iglesias JM, López-Bonet E, Martin ?G and Menendez JA: Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle 11: 4020-4032, 2012.
85. B artel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
86. Lamouille S, Subramanyam D, Blelloch R and Derynck R: Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs. Curr Opin Cell Biol 25: 200-207, 2013.
87. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G , Wang H, Siefker-Radtke A, McConkey D, et al: miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15: 5060-5072, 2009.
88. B ojmar L, Karlsson E, Elleg?rd S, Olsson H, Björnsson B, Hallböök O, Larsson M, St?l O and Sandström P: The role of microRNA-200 in progression of human colorectal and breast cancer. PLoS One 8: e84815, 2013.
89. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK and Richer JK: MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 8: 1055-1066, 2009.
90. Chen Y, Sun Y, Chen L, Xu X, Zhang X, Wang B, Min L and Liu W: miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherinmediated PTEN/Akt signaling. Mol Med Rep 7: 1579-1584, 2013.
91. Manavalan TT, Teng Y, Litchfield LM, Muluhngwi P, Al-Rayyan N and Klinge CM: Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. PLoS One 8: e62334, 2013.
92. Liu Z, Liu H, Desai S, Schmitt DC, Zhou M, Khong HT, Klos KS, McClellan S, Fodstad O and Tan M: miR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance. J Biol Chem 288: 4334-4345, 2013.
93. Wang HJ, Guo YQ, Tan G, Dong L, Cheng L, Li KJ, Wang ZY and Luo HF: miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype. J Cell Biochem 114: 2248-2257, 2013.
94. G uttilla IK, Phoenix KN, Hong X, Tirnauer JS, Claffey KP and White BA: Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res Treat 132: 75-85, 2012.
95. Ward A, Balwierz A, Zhang JD, Küblbeck M, Pawitan Y, Hielscher T, Wiemann S and Sahin ?: Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 32: 1173-1182, 2013.
96. Liu T, Zhang X, Shang M, Zhang Y, Xia B, Niu M, Liu Y and Pang D: Dysregulated expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancer. J Surg Oncol 107: 188-194, 2013.
97. Soini Y, Tuhkanen H, Sironen R, Virtanen I, Kataja V, Auvinen P , Mannermaa A and Kosma VM: Transcription factors zeb1, twist and snai1 in breast carcinoma. BMC Cancer 11: 73, 2011.
98. Jeong H, Ryu YJ, An J, Lee Y and Kim A: Epithelialmesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathology 60B: E87-E95, 2012.
99. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
100. Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M and Bonavida B: Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: Pivotal roles of Snail repression and RKIP induction. Oncogene 28: 3573-3585, 2009.
101. Shinto O, Yashiro M, Kawajiri H, Shimizu K, Shimizu T, Miwa A and Hirakawa K: Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br J Cancer 102: 844-851, 2010.
102. Li L-N, Zhang H-D, Yuan S-J, Yang D-X, Wang L and Sun Z -X: Differential sensitivity of colorectal cancer cell lines to artesunate is associated with expression of beta-catenin and E-cadherin. Eur J Pharmacol 588: 1-8, 2008.
103. Sokol JP, Neil JR, Schiemann BJ and Schiemann WP: The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta. Breast Cancer Res 7: R844-R853, 2005.
104. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N and Slamon DJ: Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/?triple-negative? breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105: 319-326, 2007.
105. Chua KN, Sim WJ, Racine V, Lee SY, Goh BC and Thiery JP: A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma. PLoS One 7: e33183, 2012.
106. Lu L, Zhou D, Jiang X, Song K, Li K and Ding W: Loss of E-cadherin in multidrug resistant breast cancer cell line MCF-7/ Adr: Possible implication in the enhanced invasive ability. Eur Rev Med Pharmacol Sci 16: 1271-1279, 2012.
107. Roger L, Jullien L, Gire V and Roux P: Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells. J Cell Sci 123: 1295-1305, 2010.
108. Z hang B, Groffen J and Heisterkamp N: Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells. Leukemia 21: 1189-1197, 2007.